Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by authority- Europäische Kommission €476m 100 % · 2 cases
What for?
by area of lawAll areas of law
Who?
by companyWhen?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 1 | €13.4m |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 1 | €462.6m |
| Q1 2025 | 0 | — |
| Q2 2025 | 0 | — |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 0 | — |
| Q3 2026 | 0 | — |
2 cases
31 Oct 2024 Teva Pharmaceutical Industries (Teva-Gruppe)EU: 462.6 million EUR against Teva for patent misuse and disparaging a competing medicine €462.6m
Teva abused its dominant position for the MS medicine Copaxone: it artificially extended patent protection by filing staggered divisional applications with the EPO and strategically withdrawing them, and spread misleading statements about an authorised competing product among physicians and decision-makers. Seven Member States were affected over periods of four to nine years.
Communications by sales representatives and medical affairs about competing products must be substantiated and objective; patent strategies of dominant companies require competition law review.
Disparaging statements about competing products to healthcare professionals
- Authority / court
- Europäische Kommission
- Area of law
- Competition law · Abuse of market power
- Legal basis
- Art. 102 AEUV
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Commission fines Teva €462.6 million over misuse of the patent system and disparagement (IP/24/5581) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
19 Oct 2023 Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, Transo-Pharm (C2 PHARMA Kronzeuge)EU: 13.4 million EUR against pharmaceutical ingredient cartel (SNBB for Buscopan) €13.4m
From 2005 to 2019, six manufacturers and traders of the active ingredient SNBB (the base substance for Buscopan and generics) fixed minimum prices, allocated quotas and exchanged sensitive information. This was the first cartel concerning an active pharmaceutical ingredient that the Commission has sanctioned; C2 PHARMA received full immunity, and all parties reached a settlement.
Even small niche markets for active ingredients are in the spotlight – contacts with competitors about prices or volumes are off-limits.
Price and quota agreements in the trade in active ingredients
- Authority / court
- Europäische Kommission
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- Art. 101 AEUV, Art. 53 EWR-Abkommen
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- Leniency programme (C2 PHARMA 100 %, Transo-Pharm 50 %, Linnea 30 %), 10 % settlement reduction
- Commission fines pharma companies €13,4 million in antitrust cartel settlement (IP/23/5104) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link